We’ve Solved Many Medical Mysteries. Where Are the Cures? | Saloni Dattani | TED

Summary

The speaker highlights remarkable progress in global health and medical innovation that often goes unnoticed because gradual improvements rarely make headlines. Heart disease mortality has dropped to a quarter of 1950s rates, and recent breakthroughs include new HIV antivirals with near-perfect efficacy, cholesterol-reducing drugs, cancer treatments, and first-time vaccines against malaria, chikungunya, and RSV. However, technology alone doesn't guarantee breakthroughs—funding, institutions, and economic incentives are equally critical barriers.

The speaker illustrates this through examples like the malaria vaccine, developed in the 1990s but delayed decades in reaching children who needed it due to lack of commercial incentive. Solutions exist and have proven effective, such as advanced market commitments that guarantee vaccine purchases, encouraging companies to invest in diseases affecting poor populations. Collaborative clinical trial networks for childhood leukemia increased survival rates from 15% to 85%, demonstrating how institutional changes can accelerate progress.

The speaker emphasizes that breakthroughs depend on people who think differently and create new incentives and systems. While frustrated by how difficult innovation remains, the speaker calls for expanding proven solutions and developing new ideas to make medical progress more efficient, especially as resources for science and global health face cuts. The core message is that diseases are solvable problems, not inevitable facts of life.

Key takeaways

• Gradual medical progress goes unrecognized as news; heart disease mortality has dropped 75% since the 1950s despite public unawareness
• Technology advances (genome sequencing costs dropped from $50M to hundreds of dollars) are necessary but insufficient without proper funding, institutions, and market incentives
• Advanced market commitments—where donors guarantee vaccine purchases if proven safe and effective—successfully incentivize development of treatments for poverty-related diseases
• Collaborative institutional networks (like leukemia trial networks) dramatically accelerate innovation by enabling larger clinical trials and knowledge sharing
• Medical breakthroughs require people willing to change systems and create new incentives; scaling existing solutions and developing new approaches is urgent as global health funding faces cuts